What We're Reading: Page 251
Industry reads hand-picked by our editors
Oct 01, 2018
Sep 28, 2018
-
The Wall Street Journal
GenScript shares drop on report alleging safety violations by unit partnered with Johnson & Johnson
-
CNBC
With food allergies on the rise, drug companies ramp up new approaches
-
Reuters
UK biotech raises bumper $2 billion, despite Brexit blues
-
Philadelphia Business Journal
Where Philadelphia ranks among the top biotech clusters
Sep 27, 2018
-
The Wall Street Journal
Young cancer patients in poor countries get a boost
-
Bloomberg
IRS weighs easing tax-free spinoff rules in boon to tech, pharma
-
Los Angeles Blade
Big Pharma fights AHF’s rent/housing initiative
-
The New York Times
Cancer center switches focus on fund-raising as problems mount
Sep 26, 2018
-
The Wall Street Journal
High hopes for a gene therapy come with fears over cost
-
Reuters
GSK vaccine success a milestone in TB, but room for improvement
-
The New York Times
Trial by Fire: Critics Demand That a Huge Sepsis Study Be Stopped
Sep 25, 2018
-
The Times
Interview: I was right to fight off Pfizer, says Astra Zeneca boss Pascal Soriot
-
The New York Times
Drug industry tries to slip $4 billion windfall into opioid bill
-
Forbes
Paralyzed patients go from wheelchairs to walkers with experimental treatment
-
The New York Times
Congratulations. Your study went nowhere.
Sep 24, 2018
Sep 21, 2018
-
The Wall Street Journal
Drugmakers’ Free Services Spur Government Scrutiny
-
The New York Times
Sloan Kettering's Cozy Deal With Start-Up Ignites a New Uproar
-
BioCentury
FDA may crack down on clinical trial reporting
-
STAT
Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial
Previous
